AP549A - Pharmaceutical composition comprising at least one quinone for use in the treatment of cancer and virus infections. - Google Patents
Pharmaceutical composition comprising at least one quinone for use in the treatment of cancer and virus infections. Download PDFInfo
- Publication number
- AP549A AP549A APAP/P/1992/000356A AP9200356A AP549A AP 549 A AP549 A AP 549A AP 9200356 A AP9200356 A AP 9200356A AP 549 A AP549 A AP 549A
- Authority
- AP
- ARIPO
- Prior art keywords
- quinone
- composition
- acid
- formula
- concentration
- Prior art date
Links
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 title claims abstract description 68
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 19
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 201000011510 cancer Diseases 0.000 title claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
- 230000009385 viral infection Effects 0.000 title abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 239000003085 diluting agent Substances 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims abstract description 8
- DGQLVPJVXFOQEV-NGOCYOHBSA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-NGOCYOHBSA-N 0.000 claims description 20
- 229940114118 carminic acid Drugs 0.000 claims description 20
- 235000012730 carminic acid Nutrition 0.000 claims description 20
- 239000004106 carminic acid Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 150000004053 quinones Chemical class 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000008367 deionised water Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000000962 organic group Chemical group 0.000 claims description 6
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 229930182482 anthraquinone glycoside Natural products 0.000 claims description 5
- 229940098421 anthraquinone glycoside Drugs 0.000 claims description 5
- 150000008139 anthraquinone glycosides Chemical class 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- BDJXVNRFAQSMAA-UHFFFAOYSA-N quinhydrone Chemical compound OC1=CC=C(O)C=C1.O=C1C=CC(=O)C=C1 BDJXVNRFAQSMAA-UHFFFAOYSA-N 0.000 claims description 4
- 229940052881 quinhydrone Drugs 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims description 3
- 150000004056 anthraquinones Chemical class 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- YEQCMRHFAWAOKU-UHFFFAOYSA-N 1,3,6-trihydroxy-8-methylanthracene-9,10-dione Chemical compound O=C1C2=CC(O)=CC(O)=C2C(=O)C2=C1C=C(O)C=C2C YEQCMRHFAWAOKU-UHFFFAOYSA-N 0.000 claims description 2
- 125000001894 2,4,6-trinitrophenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O 0.000 claims description 2
- SMUXTLISYBPIAU-UHFFFAOYSA-N desoxyerythrolaccin Natural products O=C1CC(C)CC2=C1C(C)=CO2 SMUXTLISYBPIAU-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- IHLWXZNPOVMUFQ-UHFFFAOYSA-N laccaic acid A Chemical group CC(=O)NCCC1=CC=C(O)C(C=2C(=C3C(=O)C4=C(C(O)=O)C(C(O)=O)=C(O)C=C4C(=O)C3=C(O)C=2O)O)=C1 IHLWXZNPOVMUFQ-UHFFFAOYSA-N 0.000 claims 4
- CVEVVUDMNOQKMX-UHFFFAOYSA-N 3,6,7,8-tetrahydroxy-1-methyl-9,10-dioxoanthracene-2-carboxylic acid Chemical compound O=C1C2=CC(O)=C(O)C(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C CVEVVUDMNOQKMX-UHFFFAOYSA-N 0.000 claims 2
- DJSGRCAKYFXCDH-UHFFFAOYSA-N Laccaic acid A Natural products CC(=O)NCCc1ccc(C)c(c1)c2c(O)c(O)c3C(=O)c4cc(O)c(C(=O)O)c(C(=O)O)c4C(=O)c3c2O DJSGRCAKYFXCDH-UHFFFAOYSA-N 0.000 claims 2
- YCXLCYUGBSPPJA-UHFFFAOYSA-N ceroalbolinic acid Natural products Cc1c(C(=O)O)c(O)cc2C(=O)c3c(O)c(O)c(O)cc3C(=O)c12 YCXLCYUGBSPPJA-UHFFFAOYSA-N 0.000 claims 2
- CXORMDKZEUMQHX-UHFFFAOYSA-N kermesic acid Chemical compound O=C1C2=C(O)C(O)=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C CXORMDKZEUMQHX-UHFFFAOYSA-N 0.000 claims 2
- 229910006127 SO3X Inorganic materials 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 150000003254 radicals Chemical class 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 210000001165 lymph node Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 208000007027 Oral Candidiasis Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- -1 quinones Chemical class 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- RUQPQFLYDCXMGX-UHFFFAOYSA-N Spinochrome E Natural products OC1=C(O)C(O)=C2C(=O)C(O)=C(O)C(=O)C2=C1O RUQPQFLYDCXMGX-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- DDTNCHWMNZLWKO-UHFFFAOYSA-N laccaic acid D Chemical compound O=C1C2=CC(O)=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C DDTNCHWMNZLWKO-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DGQOCLATAPFASR-UHFFFAOYSA-N tetrahydroxy-1,4-benzoquinone Chemical compound OC1=C(O)C(=O)C(O)=C(O)C1=O DGQOCLATAPFASR-UHFFFAOYSA-N 0.000 description 2
- BLDJVHTUDLDCHT-UHFFFAOYSA-N 1,2,5,7-tetrahydroxy-4-methylanthracene-9,10-dione Chemical compound O=C1C2=CC(O)=CC(O)=C2C(=O)C2=C1C(O)=C(O)C=C2C BLDJVHTUDLDCHT-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001465977 Coccoidea Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- SDYJPSSRPCAPEX-UHFFFAOYSA-N Laccaic acid D Natural products O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C SDYJPSSRPCAPEX-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000028347 Sinus disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- DCZFGQYXRKMVFG-UHFFFAOYSA-N cyclohexane-1,4-dione Chemical compound O=C1CCC(=O)CC1 DCZFGQYXRKMVFG-UHFFFAOYSA-N 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- FTEZMFWDZJWDMU-UHFFFAOYSA-N erythrolaccin Natural products Cc1cc2C(=O)c3c(O)cc(O)cc3C(=O)c2c(O)c1O FTEZMFWDZJWDMU-UHFFFAOYSA-N 0.000 description 1
- 210000001180 ethmoid sinus Anatomy 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 210000004086 maxillary sinus Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B1/00—Dyes with anthracene nucleus not condensed with any other ring
- C09B1/02—Hydroxy-anthraquinones; Ethers or esters thereof
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
- C09B67/0033—Blends of pigments; Mixtured crystals; Solid solutions
- C09B67/0034—Mixtures of two or more pigments or dyes of the same type
- C09B67/0038—Mixtures of anthraquinones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919103075A GB9103075D0 (en) | 1991-02-13 | 1991-02-13 | Trinitrobenzene derivatives and their therapeutic use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9200356A0 AP9200356A0 (en) | 1992-04-30 |
| AP549A true AP549A (en) | 1996-11-01 |
Family
ID=10689992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1992/000356A AP549A (en) | 1991-02-13 | 1992-02-12 | Pharmaceutical composition comprising at least one quinone for use in the treatment of cancer and virus infections. |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP0499467A3 (en, 2012) |
| JP (1) | JPH06505231A (en, 2012) |
| CN (1) | CN1064407A (en, 2012) |
| AP (1) | AP549A (en, 2012) |
| AU (2) | AU1233992A (en, 2012) |
| BG (1) | BG61025B1 (en, 2012) |
| BR (1) | BR9205642A (en, 2012) |
| CA (1) | CA2104009A1 (en, 2012) |
| CZ (1) | CZ166893A3 (en, 2012) |
| DZ (1) | DZ1559A1 (en, 2012) |
| FI (1) | FI933595A0 (en, 2012) |
| GB (2) | GB9103075D0 (en, 2012) |
| GT (1) | GT199200009A (en, 2012) |
| HU (1) | HUT65634A (en, 2012) |
| IE (1) | IE920464A1 (en, 2012) |
| IL (1) | IL100906A (en, 2012) |
| IN (1) | IN178929B (en, 2012) |
| IS (1) | IS3814A (en, 2012) |
| JO (1) | JO1719B1 (en, 2012) |
| LT (1) | LT3197B (en, 2012) |
| MA (1) | MA22443A1 (en, 2012) |
| MX (1) | MX9200622A (en, 2012) |
| MY (1) | MY131098A (en, 2012) |
| NO (1) | NO932681L (en, 2012) |
| NZ (2) | NZ240487A (en, 2012) |
| OA (2) | OA09535A (en, 2012) |
| SK (1) | SK87993A3 (en, 2012) |
| TN (1) | TNSN92015A1 (en, 2012) |
| WO (1) | WO1992014454A1 (en, 2012) |
| ZA (1) | ZA921037B (en, 2012) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103075D0 (en) | 1991-02-13 | 1991-03-27 | Washington Odur Ayuko | Trinitrobenzene derivatives and their therapeutic use |
| DZ1781A1 (fr) * | 1993-05-21 | 2002-02-17 | Radopah Ltd | Agents d'arylation. |
| DE69519722D1 (de) * | 1994-03-17 | 2001-02-01 | Radopath Pharmaceuticals Inter | Wirkstof gegen viren und krebs |
| ATE188870T1 (de) * | 1994-10-04 | 2000-02-15 | Lohmann Rudolf Lomapharm | Lösungen von anthrachinonen zur parenteralen applikation |
| US7482029B2 (en) | 2005-04-01 | 2009-01-27 | Bionovo, Inc. | Composition for treatment of menopause |
| US7537774B2 (en) * | 2005-12-23 | 2009-05-26 | Orion Therapeautics, Llc | Therapeutic formulation |
| JP2010535815A (ja) | 2007-08-08 | 2010-11-25 | バイオノボ・インコーポレーテッド | モクセイ科トウネズミモチのエストロゲン性抽出物およびその使用 |
| EP2194999A4 (en) | 2007-09-07 | 2012-03-21 | Bionovo Inc | ESTROGENIC EXTRACTS OF ASTRAGALUS MEMBRANACEUS FISCH.BGE.VAR.MONGOLICUS BGE. THE FAMILY LEGUMINOSAE AND ITS APPLICATIONS |
| CA2698747A1 (en) | 2007-09-07 | 2009-03-12 | Bionovo, Inc. | Estrogenic extracts of scuttelaria barbata d. don of the labiatae family and uses thereof |
| CA2698719A1 (en) | 2007-09-07 | 2009-03-12 | Bionovo, Inc. | Estrogenic extracts of asparagus conchinchinensis (lour.) merr of the liliaceae family and uses thereof |
| EP2060562A1 (en) * | 2007-11-16 | 2009-05-20 | Laboratoire Medidom S.A. | Dioxoanthracene sulphonate derivatives |
| AU2008326426A1 (en) | 2007-11-19 | 2009-05-28 | Bionovo, Inc. | Methods of detecting and treatment of cancers using scuttelaria barbata extract |
| JP2011503237A (ja) | 2007-11-19 | 2011-01-27 | バイオノボ・インコーポレーテッド | Ｓｃｕｔｅｌｌａｒｉａｂａｒｂａｔａｄ．ｄｏｎの精製抽出物を作製するためのプロセス |
| WO2009148620A2 (en) * | 2008-06-06 | 2009-12-10 | Bionovo, Inc. | Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions |
| US9884815B2 (en) * | 2011-10-14 | 2018-02-06 | Emory University | PGAM1 inhibitors and methods related thereto |
| CZ304335B6 (cs) * | 2012-02-22 | 2014-03-12 | Mikrobiologický ústav AV ČR, v. v. i. | Submerzní kmeny Quambalaria sp. CCM 8372 a CCM 8373, směs naftochinonových barviv jimi produkovaná, způsob jejich produkce a použití |
| US20210309860A1 (en) * | 2018-07-17 | 2021-10-07 | Pili | Anthraquinonic derivatives and their use as colouring agents |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5643210A (en) * | 1979-09-18 | 1981-04-21 | Koutaku Hayashi | Immunity enhancing, drug resistance preventive and carcinostatic agent |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7708452L (sv) * | 1977-07-22 | 1979-01-23 | Allied Chem | Komposition innehallande en antrakinonforening |
| JPS6043210A (ja) * | 1983-08-18 | 1985-03-07 | Tdk Corp | 磁気ヘツド及びその製造方法 |
| DE3431236A1 (de) * | 1984-08-24 | 1986-02-27 | Carnivora-Deutschland GmbH, 7109 Jagsthausen | Verwendung von 1,4-naphthochinon-derivaten in niedrigen konzentrationen zur immunstimulation |
| DE3601065A1 (de) * | 1986-01-16 | 1987-07-23 | Behringwerke Ag | Chinon-derivate als antitumormittel |
| ATE87204T1 (de) * | 1987-12-10 | 1993-04-15 | Tsumura & Co | Anti-retrovirales arzneimittel. |
| EP0580185B1 (en) * | 1988-08-16 | 1999-03-31 | The Wellcome Foundation Limited | New Naphthoquinones and their use as medicaments |
| GB9103075D0 (en) | 1991-02-13 | 1991-03-27 | Washington Odur Ayuko | Trinitrobenzene derivatives and their therapeutic use |
| EP0524212A1 (en) * | 1990-04-03 | 1993-01-27 | Radopath Limited | Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases |
| DE4013023A1 (de) * | 1990-04-24 | 1991-11-07 | Lohmann Rudolf Lomapharm | Verwendung von anthrachinonderivaten zur prophylaxe und therapie von viruserkrankungen |
-
1991
- 1991-02-13 GB GB919103075A patent/GB9103075D0/en active Pending
- 1991-11-05 NZ NZ240487A patent/NZ240487A/en unknown
-
1992
- 1992-02-10 IN IN97DE1992 patent/IN178929B/en unknown
- 1992-02-10 IL IL10090692A patent/IL100906A/en not_active IP Right Cessation
- 1992-02-11 NZ NZ241593A patent/NZ241593A/en unknown
- 1992-02-12 DZ DZ920016A patent/DZ1559A1/fr active
- 1992-02-12 MA MA22730A patent/MA22443A1/fr unknown
- 1992-02-12 IS IS3814A patent/IS3814A/is unknown
- 1992-02-12 AP APAP/P/1992/000356A patent/AP549A/en active
- 1992-02-13 JP JP4504180A patent/JPH06505231A/ja active Pending
- 1992-02-13 EP EP19920301185 patent/EP0499467A3/en not_active Withdrawn
- 1992-02-13 CZ CS931668A patent/CZ166893A3/cs unknown
- 1992-02-13 CN CN92100817A patent/CN1064407A/zh active Pending
- 1992-02-13 ZA ZA921037A patent/ZA921037B/xx unknown
- 1992-02-13 GT GT199200009A patent/GT199200009A/es unknown
- 1992-02-13 SK SK879-93A patent/SK87993A3/sk unknown
- 1992-02-13 WO PCT/GB1992/000262 patent/WO1992014454A1/en not_active Application Discontinuation
- 1992-02-13 JO JO19921719A patent/JO1719B1/en active
- 1992-02-13 BR BR9205642A patent/BR9205642A/pt not_active Application Discontinuation
- 1992-02-13 IE IE046492A patent/IE920464A1/en unknown
- 1992-02-13 CA CA002104009A patent/CA2104009A1/en not_active Abandoned
- 1992-02-13 AU AU12339/92A patent/AU1233992A/en not_active Abandoned
- 1992-02-13 OA OA60150A patent/OA09535A/en unknown
- 1992-02-13 MY MYPI92000228A patent/MY131098A/en unknown
- 1992-02-13 MX MX9200622A patent/MX9200622A/es not_active Application Discontinuation
- 1992-02-13 TN TNTNSN92015A patent/TNSN92015A1/fr unknown
- 1992-02-13 HU HU9302347A patent/HUT65634A/hu unknown
- 1992-02-13 GB GB9203084A patent/GB2254554B/en not_active Expired - Fee Related
-
1993
- 1993-02-05 LT LTIP329A patent/LT3197B/lt not_active IP Right Cessation
- 1993-07-26 NO NO93932681A patent/NO932681L/no unknown
- 1993-08-13 OA OA60399A patent/OA09810A/en unknown
- 1993-08-13 FI FI933595A patent/FI933595A0/fi not_active Application Discontinuation
- 1993-08-13 BG BG98041A patent/BG61025B1/bg unknown
-
1996
- 1996-06-11 AU AU55906/96A patent/AU5590696A/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5643210A (en) * | 1979-09-18 | 1981-04-21 | Koutaku Hayashi | Immunity enhancing, drug resistance preventive and carcinostatic agent |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP549A (en) | Pharmaceutical composition comprising at least one quinone for use in the treatment of cancer and virus infections. | |
| US8501243B2 (en) | Targeting cancer therapy combination | |
| Riordan et al. | Intravenous ascorbic acid: protocol for its application and use | |
| Schultz | Case study: high-dose intravenous vitamin C in the treatment of a patient with adenocarcinoma of the kidney | |
| WO2001052868A9 (en) | Combinations for treating neoplasms | |
| Hellmann et al. | Preliminary clinical assessment of ICRF 159 in acute leukaemia and lymphosarcoma | |
| EP0281380A2 (en) | Synergistic interplay of interleukin-2 and dsRNAs | |
| US6720011B1 (en) | Injectable composition for cancer treatment | |
| AU662883B2 (en) | Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases | |
| OA12862A (en) | Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone. | |
| JP2020537689A (ja) | Ａ−ノル−５αアンドロスタン化合物を含む白血球増多製剤およびその使用 | |
| RU2129867C1 (ru) | Средство для профилактики и лечения инфекционных заболеваний и коррекции патологических состояний живого организма | |
| HRP920891A2 (en) | Quinone preparation | |
| CN117243963B (zh) | Remodelin与Venetoclax在治疗癌症中的应用 | |
| AU651998B2 (en) | Use of a retinoid | |
| KR102576410B1 (ko) | 바실러스 균주와 5-fu를 유효성분으로 하는 대장암 치료용 약학 조성물 | |
| EP0874630A1 (en) | Topoisomerase ii poison and bis-dioxypiperazine derivative combination therapy | |
| CN116687920A (zh) | 海洋双吲哚化合物联合阿糖胞苷（Ara-C）在制备治疗急性髓系白血病（AML）药物中的应用 | |
| Slevin et al. | The pharmacokinetics of subcutaneous bolus cytosine arabinoside in an arachis oil plus aluminium distearate suspension | |
| JPH05221868A (ja) | 食細胞貪食能賦活剤 | |
| CN106039323A (zh) | ZD55‑MnSOD联合顺铂在抑制卵巢癌细胞增殖中的用途 | |
| CZ2014517A3 (cs) | Farmaceutický prostředek s virucidním a antibakteriálním účinkem | |
| MXPA97000190A (en) | Chemioprevention of colorectal polipos adenomatosos metacrono |